Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system

BMJ Open Diabetes Research and Care

Volumn 3, Issue 1, 2015, Pages

  Pantalone, Kevin M ^a   Hobbs, Todd M ^b   Wells, Brian J ^c   Kong, Sheldon X ^b   Kattan, Michael W ^a   Bouchard, Jonathan ^b   Yu, Changhong ^a   Sakurada, Brian ^b   Milinovich, Alex ^a   Weng, Wayne ^b   Bauman, Janine M ^a   Zimmerman, Robert S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NOVO NORDISK INC   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; COMPLICATION; CROSS-SECTIONAL STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 85020346886     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000093     Document Type: Article

References (21)

1. National Center for Health Statistics, Division of Health Interview Statistics. In: National Center for Chronic Disease Prevention and Health Promotion, ed. Crude and age-adjusted percentage of civilian noninstitutionalized adults with diagnosed diabetes, United States, 1980-2010. Atlanta, GA: Centers for Disease Control and Prevention, Division of Diabetes Translation, 2012.
2. http://www.cdc.gov/nchs/nhanes/about_nhanes.Htm (accessed 12 Oct 2014).
3. Cheung BMY, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-53.
4. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36:2271-9.
5. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
6. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med 2013;368:1613-24.
7. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-23.
8. Enthoven AC. Integrated delivery systems: the cure for fragmentation. Am J Manag Care 2009;15(10 Suppl):S284-90.
9. Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012;19:212-18.
10. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl 1):S14-80.
11. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23.
12. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61.
13. Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014.
14. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012;14:803-9.
15. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005;22:497-502.
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
17. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet 2005;366:1279-89.
19. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22.
20. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304:649-56.
21. Molitch ME, DeFronzo RA, Franz MJ. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1):s79-83.